# US 2026/0217716 A1 · Androgen receptor modulators and methods for their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0217716 A1
- Document ID: US20260217716A1
- Status: Published application
- Kind: A1
- Application number: 19/141,794
- Filed: 2023-12-21
- Published: 2026-07-30
- Earliest claimed: 2022-12-21
- Assignees: Capulus Therapeutics, LLC
- Applicants: Capulus Therapeutics, LLC
- Inventors: Michael John Green; Naveen Naganaboina; Ravikumar Muttineni; Sumana Ghosh
- Web page: https://patentgrep.com/patent/US20260217716A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Androgen receptor modulators, and more particularly N-terminal domain androgen receptor inhibitors, comprising a heterocyclic bicyclic [1,2,4]triazolo[4,3-b]pyridazinyl ring core, as well as pharmaceutical compositions thereof are disclosed. Such compounds target the N-terminal domain (NTD) of the androgen receptor (AR) for treating cancers such as prostate cancer and specifically metastatic castration-resistant prostate cancer (mCRPC).

## Claims

### Claim 1

A compound having a formula (I) or a pharmaceutically acceptable salt thereof:
wherein
R1 and R2 are independently a C1-C6 alkyl group optionally substituted with one or more fluorine or a C3-C6 cycloalkyl group optionally substituted with one or more fluorine;
R3 is independently at each occurrence halogen, —CN, —OR5, —C(═O)R5, —NHC(═O)R5, —C(═O)NR5R6, —NR5R6, —P(—O)—R5R6, a C1-C6 alkyl group optionally substituted with one or more fluorine, or a C3-C6 cycloalkyl group optionally substituted with one or more fluorine;
R4 is hydrogen or a C1-C6 alkyl group;
R5 and R6 are independently at each occurrence hydrogen, a C1-C6 alkyl group, or
R5 and R6 together with the nitrogen to which each is attached form a C3-C6 heterocycloalkyl group optionally substituted with one or more fluorine; and
“n” is an integer from 1 to 5.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is a C1-C6 alkyl group.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R2 is a C1-C6 alkyl group substituted with one or more fluorine.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is a C1-C6 alkyl group, and R3 is independently at each occurrence halogen, —CN, —OR4, or a C1-C6 alkyl group optionally substituted with one or more fluorine.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R2 is a C1-C6 alkyl group substituted with one or more fluorine, and R3 is independently at each occurrence halogen, —CN, —OR4, or a C1-C6 alkyl group optionally substituted with one or more fluorine.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R1 is a C1-C6 alkyl group, R2 is a C1-C6 alkyl group substituted with one or more fluorine, and R3 is independently at each occurrence halogen, —CN, —OR4, or a C1-C6 alkyl group optionally substituted with one or more fluorine.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R1 is a C1-C6 alkyl group, R2 is a C1-C6 alkyl group substituted with one or more fluorine, and R3 is independently at each occurrence halogen.

### Claim 8 (depends on 1)

The compound of claim 1 having a formula (II) or a pharmaceutically acceptable salt thereof:
wherein R1 is a C1-C6 alkyl group, R3 is independently at each occurrence halogen, —CN, —OR5, or a C1-C6 alkyl group optionally substituted with one or more fluorine, and “n” is an integer from 1 to 5.

### Claim 9 (depends on 1)

The compound of claim 1 having a formula (III) or a pharmaceutically acceptable salt thereof:
wherein R1 is a C1-C6 alkyl group, X is halogen and “n” is an integer from 1 to 5.

### Claim 10 (depends on 1)

The compound of claim 1 having a formula (IV) or a pharmaceutically acceptable salt thereof:
wherein R1 is a C1-C6 alkyl group and “n” is an integer from 1 to 5.

### Claim 11 (depends on 1)

The compound of claim 1 having a formula (V) or a pharmaceutically acceptable salt thereof:
wherein R1 is a C1-C6 alkyl group, R3 is independently at each occurrence halogen, —CN, —OR5, or a C1-C6 alkyl group optionally substituted with one or more fluorine, and “n” is an integer from 1 to 5.

### Claim 12 (depends on 1)

The compound of claim 1 having a formula (VI) or a pharmaceutically acceptable salt thereof:
wherein R1 is a C1-C6 alkyl group, X is halogen, and “n” is an integer from 1 to 5.

### Claim 13 (depends on 1)

The compound of claim 1 having a formula (VII) or a pharmaceutically acceptable salt thereof:
wherein R1 is a C1-C6 alkyl group and “n” is an integer from 1 to 5.

### Claim 14 (depends on 1)

The compound of claim 1 selected from the group consisting of:
and any pharmaceutically acceptable salts thereof.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising:
the compound of claim 1 or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, or co-crystal thereof, and
a pharmaceutically carrier, diluent, or excipient.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, comprising a compound of formula (II) or (V) or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, or co-crystal thereof:
wherein R1 is a C1-C6 alkyl group, R3 is independently at each occurrence halogen, —CN, —OR5, or a C1-C6 alkyl group optionally substituted with one or more fluorine, and “n” is an integer from 1 to 5; and
a pharmaceutically carrier, diluent, or excipient.

### Claim 17 (depends on 1)

A method for modulation of androgen receptor activity for treatment of prostate cancer, breast cancer, ovarian cancer, or melanoma, the method comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising a compound of claim 1.

### Claim 18 (depends on 17)

The method of claim 17, wherein the method comprises modulation of androgen receptor activity for treatment of metastatic castration-resistant prostate cancer.

### Claim 19 (depends on 18)

The method of claim 18 wherein the method comprises modulation of N-terminal domain of an androgen receptor for treatment of metastatic castration-resistant prostate cancer.

### Claim 20 (depends on 17)

The method of claim 17, wherein the method comprises administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (II) or (V):
wherein R1 is a C1-C6 alkyl group, R3 is independently at each occurrence halogen, —CN, —OR5, or a C1-C6 alkyl group optionally substituted with one or more fluorine, and “n” is an integer from 1 to 5.
